Pharnext Announces the Implementation of a Liquidity Contract with French Broker Gilbert Dupont

Regulatory News:

Pharnext (ISIN FR00111911287) (Paris:ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announces the implementation of a liquidity contract with French broker Gilbert Dupont.

As from 18 July, 2016, and for a period of one-year automatically renewable period, Pharnext has entered into a liquidity contract with French broker Gilbert Dupont that complies with the code of ethics issued by the AMAFI and approved by the French AMF on March 21, 2011.

For the implementation of such contract, €500,000 in cash have been credited to the liquidity account.

ABOUT PHARNEXT

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: pleotherapy. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These "pleodrugs” offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code : FR00111911287).

For more information please visit www.pharnext.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160717005074/en/